Allegro Ophthalmics Secures $10.7 Million in Funding

Allegro Ophthalmics

Represented Allegro Ophthalmics in connection with securing $10.72 million of angel funding from undisclosed investors. Allegro develops ophthalmic drugs for the treatment of wet age-related macular degeneration. It plans to use the capital to complete multiple Phase 2 clinical trials and prepare for Phase 3 studies for Luminate, its leading drug candidate.

Newport Beach-based Bruce Feuchter advised Allegro.